Precision medicine (PM) is an emerging approach for disease treatment and prevention that, beyond environment and lifestyle, mainly takes into account individual gene variability ([@R1]). PM best incorporates all the expectations raised by the most advanced pharmacological therapies in development ([@R2]). Unlike competing definitions (eg, personalized medicine) ([@R3]), PM aims to stratify (rather than individualize) pharmacological therapies to subgroups of patients who have the genetic variant of interest ([@R4]), overcoming the traditional "one size fits all" drug paradigm. Pharmacogenomics − the study of the influence of genetic variability on drug responses ([@R5]) − should help identify "the right drug at the right dose for the right patient" ([@R2]). By influencing or predicting the response to treatment ([@R1]), PM should optimize the efficacy and safety of drugs administered according to the patient's genomic profile ([@R6]), ideally maximizing pharmacological responses and minimizing the side effects ([@R7]). Since tumors tend to arise from genetic variants ([@R1]), cancer treatment has so far been the most investigated area of PM. However, longer-term expectations of PM are pharmaceutical therapies for all diseases ([@R2]).

Monoclonal antibodies (mABs) are the latest generation of drugs that fit the PM paradigm most ([@R8]). Approved in record numbers (at twice the rate of small molecules) ([@R9]) and having sky-high prices, mABs are indicated for many tumors (their main field of application) and chronic illnesses. The pharmaceutical industry expects biological markers -- molecules found in the human body that are signs of normal or abnormal processes ([@R10]) − to play a major role in using mABs for optimal treatment in clinical practice ([@R11]). The first paradigmatic example of targeted therapy in oncology was trastuzumab (with HER2 as a biomarker in breast cancer) ([@R12]), followed by cetuximab (with EGFR and KRAS in colorectal cancer) ([@R3]).

To assess the general trend of mABs and their relationship with PM, we analyzed the main characteristics of the 68 mABs approved in the European Union (EU) in the last two decades (1998-2018).

Monoclonal antibodies survey
============================

After a slow take-off, the number of mABs approved by the European Medicines Agency has dramatically increased in the last five years ([Figure 1](#F1){ref-type="fig"}). The majority of mABs approved in the second decade are human or humanized ones ([Figure 2](#F2){ref-type="fig"}), a trend which might reduce allergic reactions and boost clinical effects. The proportion of mABs indicated for cancer is still highest, although it has slightly decreased in the second decade ([Figure 3](#F3){ref-type="fig"}).

![Monoclonal antibodies approved in the European Union (EU) by years.](CroatMedJ_60_0284-F1){#F1}

![Distribution of monoclonal antibodies approved in the European Union by source.](CroatMedJ_60_0284-F2){#F2}

![Distribution of monoclonal antibodies approved in the European Union by therapeutic target.](CroatMedJ_60_0284-F3){#F3}

The European public assessment reports for half of the 26 approved anti-cancer mABs do not list a biomarker ([@R13]) ([Table 1](#T1){ref-type="table"}). Biomarkers are reported more frequently for the mABs approved for solid tumors ([@R14]), which are slightly more numerous than those for blood cancers ([@R12]) -- the latter being more curable than the former for a long time with small molecules. Of the nine biomarkers reported, all but one (Philadelphia chromosome) are proteins, and the only companion tests explicitly written in all the European reports are still those for detecting the biomarkers of the two "pioneer" targeted mABs ([@R3]).

###### 

Anti-cancer monoclonal antibodies approved in the European Union, biomarkers indicated in their labels by European Medicines Agency, and main indications (1998-2018)\*

  International nonproprietary name†   Year of approval   Biomarker                       Main indications
  ------------------------------------ ------------------ ------------------------------- -------------------------------------------------------------------------------
  Rituximab                            1998                                               non-Hodgkin lymphoma
  Trastuzumab                          2000               HER2^‡^                         breast and stomach cancer
  Cetuximab                            2004               EGFR, KRAS and NRAS^‡^          colorectal cancer
  Ibritumomab tiuxetan                 2004                                               non-Hodgkin lymphoma
  Bevacizumab                          2005               EGFR^‡^                         advanced non-small cell lung cancer
  Panitumumab                          2007               KRAS and NRAS^‡^                colorectal cancer
  Ofatumumab                           2010                                               chronic lymphocytic leukemia
  Ipilimumab                           2011                                               advanced melanoma and advanced renal cell carcinoma
  Brentuximab vedotin                  2012               CD30                            Hodgkin lymphoma
  Moxetumomab pasudotox                2013                                               B-lymphoblastic leukemia/lymphoma
  Pertuzumab                           2013               HER2^‡^                         breast cancer
  Obinutuzumab                         2014                                               chronic lymphocytic leukemia
  Ramucirumab                          2014                                               gastric cancer
  Blinatumomab                         2015               Philadelphia-chromosome, CD19   acute lymphoblastic leukemia
  Necitumumab                          2015               EGFR                            squamous non-small cell lung cancer
  Nivolumab                            2015                                               melanoma, non-small cell lung cancer
  Pembrolizumab                        2015               PD-L1                           melanoma, non-small cell lung cancer, urothelial cancer, head and neck cancer
  Daratumumab                          2016                                               multiple myeloma
  Elotuzumab                           2016                                               multiple myeloma
  Olaratumab                           2016                                               soft tissue sarcoma
  Atezolizumab                         2017               PD-L1                           urothelial cancer
  Avelumab                             2017                                               Merkel cell carcinoma
  Inotuzumab ozogamicin                2017               CD22                            acute lymphoblastic leukemia
  Gemtuzumab ozogamicin                2018               CD33                            acute myeloid leukemia
  Mogamulizumab                        2018                                               mycosis fungoides or Sézary syndrome
  Durvalumab                           2018               PD-L1                           non-small cell lung cancer

\*CD -- cluster of differentiation; EGFR -- epidermal growth factor receptor; HER2 -- human epidermal growth factor receptor 2; PD-L1 -- programmed death-ligand 1; KRAS -- Kirsten RAt Sarcoma virus; NRAS -- neuroblastoma RAS viral oncogene homolog.

^†^Source. Janice MR. The Antibody Society. Available from: <https://www.antibodysociety.org/>. Accessed: January 2019.

^‡^Companion test mentioned in the European Public Assessment Report.

Many of the more recent non-anti-cancer mABs have overlapping indications ([Table 2](#T2){ref-type="table"}). However, none of the 42 approved so far have a specific biomarker (and thus a companion test) indicated in the European reports.

###### 

Non-anti-cancer monoclonal antibodies approved in the European Union and their main indications (1998-2018)

  International nonproprietary name\*   Approval year   Main indications
  ------------------------------------- --------------- ------------------------------------------------------------------------------------------------
  Abciximab                             1995            prevention of cardiac ischemic complications, unstable angina
  Basiliximab                           1998            prevention of kidney transplant rejection
  Palivizumab                           1999            prevention of respiratory syncytial virus infection
  Infliximab                            1999            rheumatoid arthritis, Crohn\'s disease, psoriatic arthritis, psoriasis, ankylosing spondylitis
  Adalimumab                            2003            idiopathic arthritis, plaque psoriasis, Crohn\'s disease, uveitis
  Omalizumab                            2005            asthma
  Natalizumab                           2006            multiple sclerosis
  Ranibizumab                           2007            macular degeneration
  Eculizumab                            2007            paroxysmal nocturnal hemoglobinuria, atypical haemolytic uraemic syndrome
  Certolizumab pegol                    2009            rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, plaque psoriasis
  Ustekinumab                           2009            Crohn\'s disease
  Canakinumab                           2009            periodic fever syndromes, Still\'s disease, Gouty arthritis
  Golimumab                             2009            rheumatoid and psoriatic arthritis, axial spondyloarthritis, ulcerative colitis
  Tocilizumab                           2009            rheumatoid arthritis
  Denosumab                             2010            osteoporosis
  Belimumab                             2011            systemic lupus erythematosus
  Alemtuzumab                           2013            multiple sclerosis
  Raxibacumab                           2014            anthrax infection
  Siltuximab                            2014            Castleman disease
  Vedolizumab                           2014            ulcerative colitis, Crohn\'s disease
  Idarucizumab                          2015            reversal of dabigatran-induced anticoagulation
  Secukinumab                           2015            plaque psoriasis
  Mepolizumab                           2015            severe eosinophilic asthma
  Alirocumab                            2015            hypercholesterolaemia, mixed dyslipidaemia
  Evolocumab                            2015            hypercholesterolaemia, mixed dyslipidaemia
  Ixekizumab                            2016            plaque psoriasis, psoriatic arthitis
  Reslizumab                            2016            asthma
  Bezlotoxumab                          2017            prevention of recurrent *Clostridium difficile* infection
  Brodalumab                            2017            plaque psoriasis
  Guselkumab                            2017            plaque psoriasis
  Dupilumab                             2017            atopic dermatitis
  Sarilumab                             2017            rheumatoid arthritis
  Obiltoxaximab                         2018            prevention of inhalational anthrax
  Ocrelizumab                           2018            multiple sclerosis
  Emicizumab                            2018            hemophilia A
  Benralizumab                          2018            asthma
  Burosumab                             2018            X-linked hypophosphatemia
  Erenumab                              2018            migraine prevention
  Galcanezumab                          2018            migraine prevention
  Lanadelumab                           2018            hereditary angioedema attacks
  Tildrakizumab                         2018            plaque psoriasis
  Caplacizumab                          2018            acquired thrombotic thrombocytopenic purpura

\*Source: Janice MR. The Antibody Society. Available from: <https://www.antibodysociety.org/>. Accessed: January 2019.

From theory to practice
=======================

Precision medicine
------------------

Focused on biology rather than on other variables, such as lifestyle or environment, PM presents itself as the ultimate science, and its full promise goes even beyond targeting therapies for patients ([@R14]) and includes the ability to identify healthy individuals at high risk and take preventive measures for them ([@R15]). The PM's basic assumption is that genetics is the underlying factor in most health conditions, so diseases are mainly affected by the human genetic make-up ([@R16]). Progress in characterizing individual differences in genomic sequences should extend the application range of PM from rare monogenic diseases to more common and genetically complex pathologies ([@R17]). Although diseases such as cancer and diabetes are largely a consequence of lifestyles, inherited genetic variations are considered their crucial cause ([@R2]).

Politically exploited by the former president of the USA to successfully baptize a major research initiative ([@R2]), PM has aroused great expectations as a "weapon" that will defeat most human diseases in the next decades and fully transform medicine from art to science ([@R16],[@R18]). However, clinical results so far have not been as encouraging as promised. There is still a chasm between identifying a genetic susceptibility and developing safe and effective medicines. If no therapies are available, the value of diagnosis or risk stratification is very limited ([@R5]). Even more, combining various risk markers not necessarily implies providing clinically meaningful information, and much variability in therapeutic efficacy is not genetically driven ([@R16]). So, regardless of PM progress, complete success is still unlikely.

Especially for cancer, the major field of PM application, genetic mutations are numerous and evolve so heterogeneously in the majority of patients that it is almost impossible to find two identical tumors ([@R19]). This is why surgical interventions are still vital as they are the only way to immediately remove this cellular diversity from patients. There are persuasive scientific reasons why cancer has no miracle cure ([@R20]). When considered objectively, the potential of PM in oncology is sobering ([@R21]), with at best short-lived responses (and unavoidable toxicity) in a small proportion of patients, at high cost. Many of the recent successes against cancer still stem from traditional public health measures (eg, screening and early detection) ([@R22]). Although targeted therapies have so far offered limited benefit for overall survival − probably due to the adaptive nature of cancer ([@R19],[@R22]) − PM still promises to pair patients with drugs based on genetic testing irrespective of the tissue of tumor origin ([@R21]).

Monoclonal antibodies
---------------------

Our survey on the mABs approved in the EU confirmed that in practice target prioritization is still a major issue, since in most cases there is a lack of biomarkers and the biomarkers are always the same in the few mABs that report them. After two decades, the industry's mantra "no biomarker no drug" ([@R11]) has been mainly (for anti-cancer mABs) and fully (for the remaining ones) neglected in practice. Targeted therapies are still the major PM bottleneck, and "one size fits all" medicines continue to be employed ([@R21]). In oncology there are currently 343 mABs (60% of the total) under clinical trial ([@R9]), and the tendency is to treat tumors with different sites of origin with combination therapies ([@R11],[@R23]) rather than to stratify therapies for the same cancer. This tendency should help further raise the already high returns generated by anticancer mABs through their sky-high prices ([@R24]), probably distorting further investment in this field at the expense of promising research in other disease areas.

Comment
=======

Critics argue that PM is continuously fueling unrealistic expectations, distracting funds from tackling widespread risk factors such as smoking, alcoholism, and obesity ([@R5]). Although it is well known that many diseases stem from unhealthy lifestyles and socio-economic conditions ([@R22]), researchers' ambitions and media channels relentlessly foster the arguable PM promises, and keep attracting big funding ([@R14]). However, PM advocates would do better to temper their narrative of radical change and communicate a more realistic set of expectations through the media to the public ([@R5]), in line with the incremental nature of science.

While we are waiting for the gap between the exorbitant expectations raised by PM and the discouraging results achieved so far to be filled, there is widespread evidence in this period of never-ending economic crisis that pharmaceutical expenditure has become increasingly unsustainable for health authorities even in most high-income countries ([@R25]), and Europe is no exception.

Pharmaceutical expenditure, like anything else, is determined by prices and volumes, and the former are increasingly out of control. This was easy to predict in a typically "market failure" situation ([@R26]), where prices cannot competitively match demand with supply. Since all pharmaceutical prices are necessarily set through arbitrary decisions, the unavoidable results are a distortion of relative prices and irrational allocation of financial resources in pharmaceuticals ([@R27]), from upstream research investments to downstream health expenditures.

The pharmaceutical industry is mainly private, and negotiating sky-high prices for new drugs like mABs is a crucial factor of success when it comes to generating high returns on research and development investments and maximizing profits in all countries ([@R28]). In this landscape, PM helps create an ideal setting for price discrimination for new similar drugs ([@R29]), and anti-cancer mABs can be considered an emblematic example of less and less sustainable prices ([@R30]). Because of the emotive nature of cancer, health authorities find it hard to resist "pleas" for reimbursement of new drugs, even when their efficacy is marginal ([@R31]). So, pharmaceutical companies have a clear incentive to invest in new anti-cancer therapies, regardless of their real impact on patients' survival and quality of life ([@R32]).

We contend here that the time has come to stop setting arbitrary prices for new, very expensive drugs, so as to limit the distortion of allocation of financial resources in pharmaceuticals ([@R33]). Prices can hardly − if ever − be competitive in a "market failure" context, so their effect should be minimized. Leveling out prices for a very limited number of therapeutic classes and capping expenses to respect yearly budgets should become the "recipe" to master pharmaceutical expenses in the future ([@R33]). It is hard enough -- probably impossible − to rank therapies on the basis of the importance of their related pathologies, so the benefits of effective medicines are even harder to differentiate through pricing.

If we strive to restore a balance between public objectives of health services and the private incentives of the pharmaceutical industry, and improve the long-term sustainability of pharmaceutical expenditure in all European countries, rational budgeting should be given priority over irrational pricing. Realistic expectations to improve patients' health thanks to PM as a concept and mABs as therapies might then be pursued in the long run with much less suspicion in the literature.
